In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

The Capping Prescription Costs Act would cap annual out-of-pocket prescription drug costs per year at $2,000 for individuals ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Following the earnings announcement, WST stock plummeted 38% due to its disappointing guidance. Over a broader timeframe, its ...

Vaccine policy, Medicare drug negotiations, and a potential DTC advertising ban will all fall under Kennedy’s purview as HHS ...

India's Glenmark Pharmaceuticals reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Recently, a letter to the editor I wrote was published in the Arkansas Democrat-Gazette on the subject of skyrocketing health-care costs, inclusive of rising pharmaceutical drug prices. I referenced ...